Urinary activated leukocyte cell adhesion molecule (ALCAM) signatures define renal activity and therapeutic response in juvenile lupus nephritis
Authors' conclusion
Urinary ALCAM is a reliable, sensitive and non-invasive biomarker that accurately reflects renal activity and treatment response in juvenile LN.
Study context
- Population
- Pediatric patients with systemic lupus erythematosus (SLE) (juvenile lupus nephritis (LN) and SLE non-LN) and healthy controls60 pediatric SLE patients
- Participants
- 90 patients
- Exposure
- Urinary ALCAM in active LN vs active SLE non-LN vs healthy controls; active LN before vs after 3 months of treatment
- Active LNn = 30
- Active SLE non-LNn = 30
- Controlsn = 30reference
- Outcome
- Diagnostic and monitoring performance of urinary ALCAM in juvenile LN
Methodological detailscontrolled, age- and sex-matched healthy controls, 3-month follow-up in active LN
- Controlled
- Age- and sex-matched healthy controls
- 3-month follow-up in active LN
Main finding
As reported in the abstract
Baseline urinary ALCAM, median [IQR]
P < 0.001
Observational data: associations, not effects.
Further findings
| Outcome | Values | P value |
|---|---|---|
| Urinary ALCAM in active LN after 3 months of treatmentAfter treatment vs Baseline · declined significantly | After treatment 163.65 (range 85.6–238.2) ng/mg | P < 0.001 |
- Urinary ALCAM in active LN after 3 months of treatment: baseline active LN 1001.6 [766.4-1186] ng/mg
Correlations of urinary ALCAM
- Positive correlation with serum creatinine, blood urea, proteinuria, SLEDAI and renal SLEDAI; negative with eGFR
Original publication
Urinary ALCAM signatures define renal activity and therapeutic response in juvenile lupus nephritis. Pediatr Rheumatol Online J. Published 24 February 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →